Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
583
datasets available to search
ShareScore release 0.9.0
Dataset results
583 results for “prescription”
Mobile Application for Prescription Drug-Abuse Education (MAPDE)
ClinicalTrials.gov study NCT03165175. IPD Sharing: NO. Countries: 1. Publications: 4.
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study
ClinicalTrials.gov study NCT03306992. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription
ClinicalTrials.gov study NCT03588910. IPD Sharing: NO. Countries: 1. Publications: 6.
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Us
ClinicalTrials.gov study NCT01244061. IPD Sharing: Not stated. Countries: 8. Publications: 2.
STandard Versus No Opioid Prescription After Prolapse and Anti-INcontinence Surgery Trial
ClinicalTrials.gov study NCT04491617. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
ClinicalTrials.gov study NCT03936985. IPD Sharing: NO. Countries: 1. Publications: 2.
Prescription Opioid Addiction Treatment Study (POATS)
ClinicalTrials.gov study NCT00316277. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Reducing High School Athletes' Prescription Opioids Misuse and Diversion Through the Student Athlete Wellness Portal
ClinicalTrials.gov study NCT05209191. IPD Sharing: YES. Countries: 1. Publications: 1.
Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients
ClinicalTrials.gov study NCT03236155. IPD Sharing: NO. Countries: 1. Publications: 6.
Text Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids
ClinicalTrials.gov study NCT05503186. IPD Sharing: YES. Countries: 1. Publications: 1.
Benzodiazepine Taper With Cognitive Behavioral Therapy in Patients Using Prescription Opioids
ClinicalTrials.gov study NCT05573906. IPD Sharing: YES. Countries: 1. Publications: 1.
Gait analysis results for different pediatric prosthetic knee prescription protocols
Open the record for dataset details and reuse information.
CSD Opioid Prescriptions vs. Stimulants Trend
<p>Notes: The data reported in this dashboard (<a href="https://docs.google.com/spreadsheets/d/1iV2ZVv1lfD7aaN0OHZdA43RzA6VR4-7__UOWEl1WztE/edit?usp=sharing">Link</a>)reflects the data quality and reporting of controlled substance database. A new database schema was updated by DOPL in March 2017 that follows the ASAP 4.2 standard. The data is reported based on the current data. As a result, these numbers may not be consistent with previous reports. The aggregate numbers in this table does not take into account of prescription counts in CSD that were revisions (reporting status <> 02). CDC's latest drug file (2018) was used to compute these numbers. The Rx numbers are based on NDC files updated in production tables on May 2018. A new NDC file updating procedure is in progress, which might increase/decrease the MME, Rx numbers and compounds. This dashboard can be accessed at: Stimulants vs. Opioids. For any questions regarding this report contact DOPL Senior Health Informaticist, nsr@utah.gov</p>
Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada, and the United States with different regulatory controls: a cross-sectional study
<p><span><span><span><span><span><span><span><span><span><span><span><b>OBJECTIVE: </b>To assess if different forms of regulation lead to differences in the quality of journal advertisements.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>DESIGN: </b>Cross-sectional study.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>PARTICIPANTS: </b>Thirty advertisements from family practice journals published from 2013-2015 were extracted for three countries with distinct regulatory pharmaceutical promotion systems: Australia, Canada, and the United States (US). </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>PRIMARY AND SECONDARY OUTCOME MEASURES: </b>Advertisements under each regulatory system were compared concerning three domains: information included in the advertisement, references to scientific evidence, and pictorial appeals and portrayals. An overall ranking for advertisement quality among countries was determined using the first two domains as the information assessed has been associated with more appropriate prescribing. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>RESULTS: </b>Advertisements varied significantly for number of claims with quantitative benefit (Australia: 0.0 (0.0-3.0); Canada: 0.0 (0.0-5.0); US: 1.0 (0.0-6.0); p=0.01); statistical method used in reporting benefit (RRR, ARR, and NNT) (Australia: 6.7%, n=2; Canada: 10.0%, n=3; US: 36.6%, n=11; p=0.02); mention of adverse effects, warnings, or contraindications (Australia: 13.3%, n=4; Canada: 23.3%, n=7; US: 53.3%, n=16; p=0.002); equal prominence between safety and benefit information (Australia: 25.0%, n=1; Canada: 28.6%, n=2; US: 75.0%, n=12; p=0.04); and methodologic quality of references score (Australia: 0.4150 (0.25-0.70); Canada: 0.25 (0.00-0.63); US: 0.25 (0.00-0.75); p<0.001). The US ranked first, Canada second, and Australia third for overall quality of journal advertisements. Significant differences for humor appeals (Australia: 3.3%, n=1; Canada: 13.3%, n=4; US: 26.7%, n=8; p=0.04), positive emotional appeals (Australia: 26.7%, n=8; Canada: 60.0%, n=18; US: 50.0%, n=15; p=0.03), social approval portrayals (Australia: 0.0%, n=0; Canada: 0.0%, n=0; US: 10.0%, n=3; p=0.04), and lifestyle or work portrayals (Australia: 43.3%, n=13; Canada: 50.0%, n=15; US: 76.7%, n=23; p=0.02) were found among countries.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>CONCLUSIONS:</b> <a name="_Hlk34742358">Different regulatory systems influence journal advertisement quality concerning all measured domains. </a>However, differences may also be attributed to other regulatory, legal, cultural, or health system factors unique to each country.</span></span></span></span></span></span></span></span></span></span></span></p>
Data from: Co-prescription network reveals social dynamics of opioid doctor shopping
This paper examines network prominence in a co-prescription network as an indicator of opioid doctor shopping (i.e., fraudulent solicitation of opioids from multiple prescribers). Using longitudinal data from a large commercially insured population, we construct a network where a tie between patients is weighted by the number of shared opioid prescribers. Given prior research suggesting that doctor shopping may be a social process, we hypothesize that active doctor shoppers will occupy central structural positions in this network. We show that network prominence, operationalized using PageRank, is associated with more opioid prescriptions, higher predicted risk for dangerous morphine dosage, opioid overdose, and opioid use disorder, controlling for number of prescribers and other variables. Moreover, as a patient's prominence increases over time, so does their risk for these outcomes, compared to their own average level of risk. Results highlight the importance of co-prescription networks in characterizing high-risk social dynamics.
Predictive genetic plan for a captive population of the Chinese goral (Naemorhedus griseus) and prescriptive action for ex situ and in situ conservation management in Thailand
<p>Captive breeding programs for endangered species can increase population numbers for eventual reintroduction to the wild. Captive populations are typically small and isolated, which results in inbreeding and reduction of genetic variability, and may lead to an increased risk of extinction. The Omkoi Wildlife Breeding Center maintains the only Thai captive Chinese goral (<i>Naemorhedus griseus</i>) population, and has plans to reintroduce individuals into natural isolated populations. Genetic variability was assessed within the captive population using microsatellite data. Although no bottleneck was observed, genetic variability was low (allelic richness = 7.091 ± 0.756, <i>H</i><sub>e</sub> = 0.455 ± 0.219; <i>H</i><sub>e</sub> < <i>H</i><sub>o</sub>) and 11 microsatellite loci were informative that likely reflect inbreeding. Estimates of small effective population size and limited numbers of founders, combined with wild-born individuals within subpopulations, tend to cause reduction of genetic variability over time in captive programs. This leads to low reproductive fitness and limited ability to adapt to environmental change, thereby increasing the risk of extinction. Management of captive populations as evolutionarily significant units with diverse genetic backgrounds offers an effective strategy for population recovery. Relocation of individuals among subpopulations, or introduction of newly captured wild individuals into the captive program will help to ensure the future security of Chinese goral. Implications for future conservation actions for the species are discussed herein.</p>
Effectiveness of a multicomponent intervention consisting of education and feedback on reducing benzodiazepine prescriptions by general practitioners: BENZORED hybrid type I cluster randomized controlled trial.
<p>Complete dataset variables:</p> <p> </p> <p>GP_ID<br> Health_District<br> Health_District_name<br> PHC_ID<br> PHC_ID_name<br> Arm<br> DHD_Baseline<br> DHD_12m<br> PercentageBZD_baseline<br> PercentageBZD_12m<br> PercentageBZD_baseline_age65<br> PercentageBZD_12m_age65</p>
Dataset for Desai et al. "Reporting of drug benefit in FDA-approved prescription drug labeling"
<p>All FDA labels and extraction sheets to support our paper, Desai et al. "Reporting of drug benefit in FDA-approved prescription drug labeling".</p>
Correlation between the introduction of gastrointestinal PCR panels and the antibiotic prescription in outpatients with gastroentiritis
<p>Excel table summarising the data of 2 cohorts having symptoms of gastroenteritis:</p> <p>- cohort from 2016 investigated by traditional methods</p> <p>- cohort from 2017 investigated by gastrointestinal PCR panels</p>
Stellar models for "A prescription for the asteroseismic surface correction" by Li, Yaguang et al. (2023)
<p>This folder publishes the stellar models utilized in Li et al. (2023)</p> <p> </p> <p>The stellar models presented here encompass a range of parameters: mass (0.7, 2.3) solar mass, Yinit (0.22, 0.32), [M/H] within (-0.94, 0.56) dex, and amlt (1.3, 2.7). All evolutionary tracks are calculated up to the point on the RGB when the p-mode large separtion Dnu equals 2 muHz.</p> <p> </p> <p>Each model entry (row) are presented with classical observables (Teff, radius, luminosity, ...) and radial modes (mode_freq, mode_inertia, mode_n, ...)</p> <p> </p> <p>For a comprehensive description of the stellar models, please refer to the paper.</p> <p> </p> <p>The folder contains three sets of stellar models. These models are stored in the "npy" format. They can be read in Python using the following code: "import numpy as np; data = np.load(filename, allow_pickle=True);"</p> <p><br> </p> <p>- grid_models_surface_effect_corrected/tracks*.npy</p> <p>This set includes stellar models with frequencies that have surface effect removed.</p> <p> </p> <p>- grid_models_surface_effect_uncorrected/tracks*.npy</p> <p>This set includes stellar models with frequencies in the original uncorrected format.</p> <p> </p> <p>- stats_models_for_fDnu_ANN_weights.npy</p> <p>This file is a statistical stellar model fitted by an artificial neural network with fully connected layers. It can be used for calculating fDnu, the correction factor of the Dnu scaling relation, or for doing any stellar parameter inference using global parameters (such as numax, Dnu, Teff, lum, etc.). More details and example use cases can be found at https://github.com/parallelpro/surface/</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.